| Primary information |
|---|
| ID | antitb_1331, |
| Name | 23555622 |
| N-Terminal modification | Innate defence regulator peptide HH2 |
| C-Terminal Modification | VQLRIRVAVIRA |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 12 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Inhibition Concentration | Both |
| Sequence | 2012 |
| Cytotoxicity | Human U937 promonocytic cell line |
| In vivo Model | NA |
| Lethal Dose | None |
| Immune Responce | BALB/C |
| Mechanism of Action | 32 mg in 100 mL of saline solution (1 mg/kg) |
| Target | Increase expression of MCP-1,Gro-α and TNF-α |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antimicrobial against plasmodium aeruginosa/ S. aureus |
Tertiary Structure
(Technique) | Not Predicted), |